Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30108401 | 1.00 | CYP3A4 (0.32) | CYP3A4MIFGABRA1GABRB2CYP1A2 | |
| SCHEMBL12865532 | 0.84 | APOBEC3G (0.31) | — | |
| SCHEMBL1009278 | 0.84 | MIF (0.44) | CYP3A4MIF | |
| SCHEMBL707583 | 0.80 | CYP3A4 (0.34) | CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL28048338 | 0.77 | LIPG (0.46) | CYP3A4CYP2D6 | |
| SCHEMBL28536551 | 0.77 | GABRA1 (0.50) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL28658322 | 0.77 | GABRA1 (0.42) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL11167797 | 0.74 | APLNR (0.34) | — | |
| Pyridine SCHEMBL7848227 | 0.74 | MIF (0.36) | MIF | |
| SCHEMBL18245040 | 0.73 | NOS3 (0.36) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305064-A1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | Anika Therapeutics Inc. (US) | 2003-05-02 | — | — | EP | claimed |
| WO-2002009792-A1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | ANIKA THERAPEUTICS, INC. (US) | 2002-02-07 | — | — | WO | claimed |
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | GLYCOLOGIX INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11975019-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | GLYCOLOGIX, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11911411-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | GLYCOLOGIX, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4121064-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | Glycologix, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20220000905-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | GLYCOLOGIX, INC. | 2022-01-06 | — | — | US | disclosed |
| WO-2021188882-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | GLYCOLOGIX, LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210290657-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | GLYCOLOGIX, LLC | 2021-09-23 | — | — | US | disclosed |
| US-11090327-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | GLYCOLOGIX, LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190262386-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | GLYCOLOGIX, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-1968499-A1 | BIOABSORBABLE IMPLANT OF HYALURONIC ACID DERIVATIVE FOR TREATMENT OF OSTEOCHONDRAL AND CHONDRAL DEFECTS | Anika Therapeutics Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1968614-A2 | TREATMENT OF ARTHRITIS AND OTHER MUSCULOSKELETAL DISORDERS WITH CROSSLINKED HYALURONIC ACID | Anika Therapeutics Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007070547-A2 | TREATMENT OF ARTHRITIS AND OTHER MUSCULOSKELETAL DISORDERS WITH CROSSLINKED HYALURONIC ACID | ANIKA THERAPEUTICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070546-A2 | MENISCAL IMPLANT OF HYALURONIC ACID DERIVATIVES FOR TREATMENT OF MENISCAL DEFECTS | ANIKA THERAPEUTICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070617-A1 | BIOABSORBABLE IMPLANT OF HYALURONIC ACID DERIVATIVE FOR TREATMENT OF OSTEOCHONDRAL AND CHONDRAL DEFECTS | ANIKA THERAPEUTICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1699500-A1 | CROSSLINKED HYALURONIC ACID COMPOSITIONS FOR TISSUE AUGMENTATION | Anika Therapeutics Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005067994-A1 | CROSSLINKED HYALURONIC ACID COMPOSITIONS FOR TISSUE AUGMENTATION | ANIKA THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-1305064-A1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | Anika Therapeutics Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002009792-A1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | ANIKA THERAPEUTICS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | MATR3, CSGALNACT1, CD44 | CYP3A4 4706/4885MIF 702/4885GABRA1 4171/4885 |
| US-20190262386-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | CSGALNACT1, MATR3, CD44 | CYP3A4 4327/4885MIF 571/4885GABRA1 3856/4885 |
| US-20220000905-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | CSGALNACT1, MATR3, CD44 | CYP3A4 4327/4885MIF 571/4885GABRA1 3856/4885 |
| US-11090327-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | CSGALNACT1, MATR3, CD44 | CYP3A4 4327/4885MIF 571/4885GABRA1 3856/4885 |
| US-11911411-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | MATR3, CSGALNACT1, CD44 | CYP3A4 4706/4885MIF 702/4885GABRA1 4171/4885 |
| US-11975019-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | CSGALNACT1, MATR3, CD44 | CYP3A4 4327/4885MIF 571/4885GABRA1 3856/4885 |
| US-20210290657-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | MATR3, CSGALNACT1, CD44 | CYP3A4 4706/4885MIF 702/4885GABRA1 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.